We found no difference in proteinuria, albuminemia, serum creatinine, urea, lymphocyte count, anti-PLA2R1 activity and remission between IL-17A-positive and IL-17A-negative patients but IL-17A positive patients presented more thromboembolic complications (phlebitis, pulmonary embolism, renal vein thrombosis) and relapsed more often (P=0.03 and P=0.0006, respectively, Table 2). Here, PLA2R1 is linked to pulmonary embolism.